In 1976, Genentech, the first biotechnology company, was founded by a young venture capitalist and a university professor to exploit recombinant DNA technology. Thirty years and more than $300 billion in investments later, only a handful of biotech firms have matched Genentech's success or even shown a profit. No avalanche of new drugs has hit the market, and the long-awaited breakthrough in R&D productivity has yet to materialize. This disappointing performance raises a question: Can organizations motivated by the need to make profits and please shareholders successfully conduct basic scientific research as a core activity?
From the October 2006 issue of Harvard Business Review.
Want more Harvard Business Review?
Subscribe for one month or 12 months.
Get the latest issue.
Check out the complete archive.
©2006 by the President and Fellows of Harvard College, All Rights Reserved; (P)2006 Audible Inc.